Detail akcie Biogened online

Business Summary: Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, BIOGENED SA revenues increased 20% to PLN95.6M. Net income increased 24% to PLN4.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other Operating Expense decrease of 87% to PLN1M (expense), G/L on Sale of Tangible & Intangible F increase from PLN34K to PLN875K (income).